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ABSTRACT
OPTIMATION OF RHENIUM-OXO-GLUCONATE SYNTHESIS AS A PRECURSOR FOR
SYNTHESIS OF RHENIUM(V)-TETROFOSMIN. Rhenium-188 or Rhenium-186 labeled compounds have
been widely used as therapeutic radiopharmaceutical for cancer. Most of rhenium (Re) radiopharmaceuticals
involve Re with oxidation state of 5, one of which is Re-dioxo-tetrofosmin. Complexes of Re(V)-ligand can be
generated from Re(V)-oxo-gluconate through ligand exchange process. Optimation of rhenium-oxo-gluconate
synthesis was carried out by varying mole ratio of gluconate to perrhenate and reaction time, in which 188Re
was added to perrhenate solution as radiotracer. Stability study of Re-oxo-gluconate at room temperature and
elevating temperature was carried out by measuring its radiochemical purity within several hours. Radiochemical
purity was analysed using 2 systems of paper chromatography with Whatman-3 paper as solid phase, and
acetone and saline as mobile phases, respectively. Highest yield was obtained using mole ratio of 6000, i.e
87.43% (SD=3.01%), and the optimum reaction time was 1 hour. Storage at room temperature and elevating
temperature resulted in the decrease of radiochemical purity of 10% (within 3 hrs) and 30% (within 1 hour),
respectively. Re-dioxo-tetrofosmin which was used as a model of Re(V)-ligand, was obtained through ligand
exchange reaction with the yield of 92.1%. The result showed that Re-oxo-gluconate can be successfully
synthesized in high yield but low stability.
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ABSTRAK
OPTIMASI SINTESIS RENIUM-OKSO-GLUKONAT SEBAGAI PREKURSOR UNTUK
SINTESIS RENIUM (V)-TETROFOSMIN. Senyawa bertanda Renium-188 atau Renium-186 sudah digunakan
secara luas sebagai radiofarmaka terapi kanker. Sebagian besar radiofarmaka bertanda renium (Re) melibatkan
Re dengan bilangan oksidasi 5, antara lain Re-diokso-tetrofosmin. Reaksi kompleksasi Re(V)-ligan dapat
diturunkan dari Re(V)-okso-glukonat melalui proses pertukaran ligan. Telah dilakukan optimasi sintesis renium-
okso-glukonat dengan memvariasikan perbandingan mol glukonat terhadap perrenat dan memvariasikan waktu
reaksi, dengan menambahkan 188Re kedalam larutan perrenat sebagai perunut. Studi kestabilan Re-okso-glukonat
pada suhu kamar dan suhu yang dinaikkan dilakukan dengan mengukur kemurnian radiokimianya selama beberapa
jam. Kemurnian radiokimia Re-okso-glukonat dianalisis dengan 2 sistem kromatografi menggunakan kertas
Whatman-3 sebagai fasa diam, dengan fasa gerak berturut-turut aseton dan salin (larutan natrium klorida 0,9%).
Perbandingan mol 6000 : 1 menghasilkan senyawa kompleks dengan tingkat kemurnian radiokimia tertinggi
yaitu 87,43% (SD=3,01%), serta waktu reaksi optimum pada 1 jam. Penyimpanan senyawa kompleks pada
suhu kamar dan suhu yang dinaikkan menyebabkan penurunan kemurnian radiokimia berturut-turut sebanyak
10% (dalam waktu 3 jam) dan 30% (dalam waktu 1 jam). Re-diokso-tetrofosmin yang digunakan sebagai model
dari senyawa kompleks Re(V)-ligan, berhasil diperoleh melalui reaksi pertukaran ligan dengan kemurnian
radiokimia 92,1%. Dari percobaan ini disimpulkan bahwa Re-okso-glukonat telah berhasil disintesis dengan
rendemen yang tinggi namun kestabilannya rendah.
Kata kunci: Re-okso-glukonat, Renium-188, Sintesis, Kemurnian radiokimia, Tetrofosmin
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INTRODUCTION
Radiopharmaceuticals for detecting heart disease
and tumor are commonly used in nuclear medicine in
Indonesia, two of them are technetium-99m sestamibi
(99mTc-MIBI) and 99mTc-tetrofosmin [1-7]. In-vivo
stability of 99mTc radiopharmaceuticals can be predicted
through biodistribution during the use, but ideally it has
been studied previously. Radiochemical stability of 99mTc-
tetrofosmin can be studied rather than chemical stability,
because it can only be obtained in a very small
concentration which making it impossible to be analysed
using chemical instruments. Molecular structure of Re-
tetrofosmin is assumed to be the same as that of Tc-
tetrofosmin, so Re-tetrofosmin can be used as a model
to study in-vitro stability of Tc-tetrofosmin since Re-
tetrofosmin can be synthesized in micro scale without
using radioactive rhenium [8-9].
Rhenium and technetium have similar chemical
properties since they belong to VIIB group in periodic
table known as transition metals, so they have similarity
especially in terms of the ability to form complex
compounds with ligands. Non radioactive rhenium is
available in nature rather than technetium, so that
chemical properties and stability of rhenium tetrofosmin
can be studied using chemical instruments. Therefore
rhenium can be used as a model to study and predict
the behavior of technetium radiopharmaceutical in-vivo
[8-9].
Rhenium-ligand complexes have been widely
used as therapeutic radiopharmaceuticals for cancer,
accordingly literatures related with the development of
rhenium radiopharmaceuticals can be easily obtained
[10-15].
Rhenium and technetium in the reduced state are
relatively unstable and easily reoxidised by oxygen in
the air or solution, so the interference of oxygen has to
be minimized. Reducing agent such as stannous chloride
is required in higher amounts and the addition of
antioxidant such as ascorbic acid is sometimes required.
As of technetium, rhenium has oxidation state of 0, +1,
+2, +4, +6 and +7, from which the most stable state is 7
and the most widely used is 5. Molecular structure of
Re-tetrofosmin is assumed to be the same as that of Tc-
tetrofosmin (Figure 1), which is called Re-dioxo-
tetrofosmin since two oxygen atoms are attached to Re
[16-17].
Rhenium has higher potential of oxidation than
technetium, making it more difficult to reduce its oxidation
state proceed with the formation of Rhenium complex
compound. To accomplish the reaction, stannous
chloride as reducing agent is required in higher amount
and the reaction is carried out in an atmosphere of
nitrogen or argon to avoid the presence of oxygen which
can oxidize Sn (2+) and reoxidize Re (5+) to Re (7+).
Complexation of Tc(V)-dioxo- tetrofosmin or trans-
diokso Tc (V) diphosphine is usually slow and unstable
but can be accelerated and stabilised by the addition of
co-ligand that serves as transchelator such as sodium
D-gluconate, then the process of ligand exchange
(gluconate will be replaced by tetrofosmin) can be
accelerated by increasing the concentration of
tetrofosmin or heating [16-19].
Protocol for synthesizing Tc-tetrofosmin is
available in several journals but it can not be applied to
Re-tetrofosmin, so for this purpose it needs another
approach. Re-oxo-gluconate is commonly used as a
precursor for synthesising Rhenium complex compound
with oxidation state of 5. Since oxidation state of Re in
the compound of Tc-tetrofosmin is also 5 so the reaction
of Re with tetrofosmin can be carried out using Re-oxo-
gluconate pathway. For this purpose radioactive rhenium
either 186Re or 188Re can be added as a tracer [16-19].
Study and preparation of carrier free 188Re-oxo-
gluconate was reported with radiochemical purity of over
90% but the stability is low[18-19]. The term carrier means
an isotope (usually non-radioactive) that is added to
the radioactive atoms to facilitate the reaction, for
example non radioactive 185Re that is added to 188Re in
the labeling process or synthesis of radiolabeled
compound.
As in Tc-tetrofosmin complex compounds, prior
to formation of Re-tetrofosmin previously oxidation state
of Re has to be reduced from 7 to 5 through the
establishment of Re-oxo-gluconate as an intermediate
complex/chelate which takes 1-2 hours at pH 5. To
accomplish the reaction, stannous chloride as reducing
agent is required in higher amount and the reaction is
carried out in an atmosphere of nitrogen or argon to
avoid the presence of oxygen which can oxidize Sn (2+)
and reoxidize Re (5+) to Re (7+) as can be seen in the
equation (1) and (2) [16-22].
[ReO4]
- + Sn+2 + Na-gluc.  [ReO(gluc.)2]
- + Sn+4 .. (1)
[ReO(gluc.)2]
- + tetrofosm.[ReO2 (tetrofosm.) 2]
++
Na-gluc. .............. (2)
The yield of synthesis is represented by
percentage of radiochemical purity or radiolabeling
yield which is used as test parameter. The
radiochemical purity of both Re-oxo-gluconate and
Re-dioxo-tetrofosmin was analysed using paperFigure 1. Molecular structure of 99mTc-dioxo-tetrofosmin.
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chromatography, thin layer chromatography and
Sep-Pak C18 column [23-25].
Based on literature searching, the research
regarding carrier added 186/188Re-tetrofosmin synthesis
nor the study of physico-chemical characteristics of non
radioactive rhenium tetrofosmin has not been done
anywhere, so approach has been made through the route
of carrier-added 188Re-oxo-gluconate synthesis which
also has not been reported anywhere. To synthesize
carrier-added 188Re-oxo-gluconate, optimation of several
reaction parameters need to be conducted.
This experiment was carried out to obtain optimum
condition in synthesizing rhenium-oxo-gluconate in
micro scale to be used as precursor for rhenium-dioxo-
tetrofosmin synthesis. Non radioactive rhenium-dioxo-
tetrofosmin will then be used to study in-vitro stability
of 99mTc-tetrofosmin in blood serum. The aim of this study
is to support the development of technetium-99m




The material used are tetrofosmin (ABX), sodium
D-gluconate (Sigma-Aldrich), stannous chloride
dihydrate (Sigma-Aldrich), glacial acetic acid (Merck),
sodium acetate (Merck), nitrogen gas (high purity,
medical grade) , ammonium perrhenate (Merck), a
solution of perrhenate 188Re obtained from 188W / 188Re
generator (PTRR-Batan), acetone, methylene chloride,
physiological NaCl solution (saline) and other materials.
The equipment used are chromatography
chamber supported with Whatman-3 paper strips
(Merck), TLC-SG strips (Merck), gamma management
system (DPC), TLC scanner (Bioscan), glassware and
other equipment.
Methods
Synthesis method used was referred to the
synthesis method of rhenium gluconate which serves
as precursors to the formation of complex compounds
based on rhenium (V) oxo ligand [16-19]. Synthesis of
rhenium tetrofosmin was carried out by transchelation
process in which gluconate was replaced or substituted
by tetrofosmin. Re-gluconate synthesis was performed
by reacting sodium gluconate 0.5 M (in 0.2 M sodium
acetate solution) with 0.04 mg of potassium perrhenate
(solution of 1 mg/mL in water) added with 188Re of
0,1 mCi and 0.1 mL of solution SnCl2 dihydrate (solution
of 20 mg/mL in 10% acetic acid) for 1-2 hours [7]. The
reaction was carried out in a sealed container with a
nitrogen gas atmosphere for 15 minutes and then the
atmosphere containing N2 gas was maintained by
covering the container with a balloon that was developed
with N2 gas as can be seen in Figure 2.
Re-oxogluconate formation was identified by
paper chromatography using Whatman-3 paper as
stationary phase eluted with acetone (system 1) and
saline (system 2). In system 1 Re-oxogluconate and Re
oxide (rhenium colloid) retained at the base (Rf 0) while
perrhenate eluted to the front at Rf 1. In system 2 Re-
oxogluconate and perrhenate (free perrhenate) eluted to
the front at Rf 0.8 while ReO2 colloids retained at the
base at Rf 0 [16-19].
Radioactivity of the product in the
chromatograms was measured by Gamma Management
System (GMS) and TLC scanner (Bioscan).
Radiochemical purity of the product was analysed
using paper chromatography detected by
radiochromatography scanner with in-line gamma
detector (Bioscan), alternatively, Gamma Management
System (GMS) was also used as a routine application
when the radioactivity was getting low (less than 1 mCi).
Optimation of the synthesis was done by varying the
amount of gluconate and reaction time, whereas the
stability of the complex compound was observed within
several hours both with and without heating.
Transchelation process or formation of Re-dioxo
tetrofosmin was carried out by adding 0.3 mL of Re-
oxogluconate into 0.1 mL of an aqueous solution
containing 1 mg of tetrofosmin, heating at 95C for
15 minutes and allowed to stand for 30 minutes.
The yield was measured by thin-layer
chromatography using TLC-SG strips as stationary phase
and mixture of acetone-dichloromethane (35: 65) as
mobile phase, in which Re oxide colloid retained at the
base at Rf 0 while perrhenate or free Re eluted at Rf 1 and
Re-dioxo tetrofosmin eluted to the middle of the strips
at Rf 0.5.
RESULTS AND DISCUSSION
Synthesis of 188Re-oxo-gluconate using no-
carrier-added 188Re (not containing non-radioactive Re)
Figure 2 . Ilustration of synthesis process of
Re-oxogluconate
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resulted in a low yield of 188Re-oxo gluconate of 68.5%,
but the yield increased to 92.4% after using twice amount
of stannous chloride. It conformed the result according
to Noll et al. [18-19] that the yield is around 80-90%.
Radiochemical purity of the product was analysed
using paper chromatography detected by
radiochromatography scanner with in-line gamma
detector, and the performance of radiochromatogram was
as in Figure 3.
The reaction pH required for the complexation of
Re-oxo gluconate as well as Re-dioxo tetrofosmin was
4-5 in contrast to the alkaline pH required for the
complexation of 99mTc-tetrofosmin. Increasing the
amount of reducing agent to a certain extent can improve
the yield of Re-oxo gluconate and reduced the
perrhenate as impurity.
In the formation of 188Re-gluconate with addition
of carrier or non-radioactive perrhenate resulted a low
radiochemical purity product of 39.3% which perrhenate
and Re colloid impurity of 15% and 45.7% respectively.
The addition of non-radioactive perrhenate to the
reaction mixture lowered radiochemical purity, this is due
to the insufficiency of ligand in this case was gluconate
which resulted the hydrolysis of reduced perrhenate into
Re oxides colloid and reoxidation small part of reduced
perrhenate to perrhenate. Addition of sodium gluconate
2.5 times folded to the reaction increased radiochemical
purity significantly from 39.3% to 87.43% (SD = 3.01%, n
= 3) in which the impurity is perrhenate (12.6%). This
indicates that most of perrhenate reduced to Re (V)
forming complexes of Re (V) oxo gluconate.
In the same experiment in which the reaction time
was varied at 1, 1.5 and 3 hours, resulting in radiochemical
purity of Re-oxogluconate with no significant difference
between reaction time of 1 and 1.5 hours, i.e 82.28%
(SD=2), but using reaction time of 3 hours the
radiochemical purity decreased slightly to 79.14%
(SD=4.35%), as can be seen in Figure 4.
The slight decline in the radiolabeling yield of
Re-gluconate indicated that the addition of reaction time
did not lead to an increase in the yield but even lowered
the stability of complex. This suggests that Re-gluconate
compound has relatively low stability, so that Re (V)
was reoxidized back to Re (VII). Thus the optimal reaction
time for the synthesis of Re-gluconate is 1 hour.
Instability of Re-oxogluconate was also observed
when the reaction mixture was heated at 95C for 15
minutes and then incubated up to 1 hour, in which the
radiochemical purity decreased from 89.26% to 59.5%
(Figure 5). This was caused by disruption of the stability
of the complex by heat so that a small portion of Re (V)
was reoxidized into Re (VII) or perrhenate.
The same experiment using carrier added 186Re
(perrhenate Re-186 solution which contained non-
radioactive Re by an amount equal to the previous
experiment) resulted in a high yield of Re-oxogluconate
i.e 96.1% radiochemical purity with 3.9% of perrhenate
impurity. The use of carrier-added 186Re which contained
Figure 4. The stability of Re-oxogluconate observed
within 3 hours.
Figure 5. Stability decrease of Re-oxogluconate with and
without heating.
Figure 3. Peak of 188Re-oxo gluconate in chromatogra-
phy system with acetone as eluant (top) and peak
of 188Re-oxo gluconate in system with saline as eluant
(bottom)
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15 mg/ ml of non radioactive Re in a volume of 0.7 ml
provided higher yield compare with that using 188Re
which total volume was 1.6 ml, this was due to the more
concentrated reaction mixture which cause sufficient
contact between reactant molecules resulting in a greater
probability of reaction.
The experiment using no carrier-added 188Re
showed slightly lower yield compared with that of
186Re, because of moderate volume of reaction mixture
(Figure 6).
Re-oxogluconate obtained from the optimised
condition of reaction was used to synthesise Re-dioxo
tetrofosmin, resulted in 92.4% (SD=2.06, n=3) yield of
Re-dioxo tetrofosmin. Tetrofosmin required for the
reaction was in excess with mole ratio of 2000 times to
the mole of potassium perrhenate used. The process
was carried out by heating the reaction mixture in 15
minutes followed by incubating for 30 minutes in room
temperature.
CONCLUSION
Formation of Re-oxogluconate resulted with high
yield in 1 hour, but the stability is low. The amount of
sodium D-gluconate as ligand should be in excess due
to the slow reaction. Due to the low stability of Re-
oxogluconate, it is unlikely to characterize it using
chemical instruments. For the next experiment it is
suggested to add an antioxidant such as ascorbic acid
to increase the stability of Re-oxogluconate.
Re-dioxotetrofosmin can be synthesised in high
yield from transchelation process of Re-oxogluconate,
in which the amount of tetrofosmin as the main ligand
has to be in excess. It can be concluded that Re-
oxogluconate synthesis pathway can be used to
synthesize Re-dioxo-tetrofosmin.
It is suggested to use this method in the
development of other Re(V)-ligand complexes for
therapeutic radiopharmaceuticals.
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